Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer

Background/Aim: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy. Patients and Methods: We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity >= 85%. Results: In the pegfilgrastim vs. the control group, body mass index (26.6 +/- 5.9 vs. 23.4 +/- 4.4), rate of relative dose intensity >= 85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0 +/- 2.1 vs. 18 +/- 5.6 days), unscheduled hospital visits (1.1 +/- 1.8 vs. 5.8 +/- 5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58 +/- 1.7 vs. 6.4 +/- 5.1 days) were significantly lower. Conclusion: Pegfilgrastim can maintain a dose intensity of >= 85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency.